Methods for producing modified reverse transcriptases
US-2024124856-A1 · Apr 18, 2024 · US
Anti-inflammatory peptides and composition comprising the same
US2022331407A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2022331407-A1 |
| Application number | US-202217835278-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 8, 2022 |
| Priority date | May 11, 2012 |
| Publication date | Oct 20, 2022 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, a peptide comprising a sequence of SEQ ID NO: 1 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptide of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.
First claim
Opening claim text (preview).
1 - 16 . (canceled) 17 . A method for preventing or treating dermal related inflammatory disease comprising administering to a subject in need thereof a composition comprising the isolated peptide of SEQ ID NO: 1. 18 . The method according to claim 17 , wherein the dermal related inflammatory disease is selected from the group consisting of psoriasis, burns, sunburns, dermatitis, urticarial warts, and wheal. 19 . The method of claim 17 , wherein the composition is administered through oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, in the bone marrow, epidural, or subcutaneous means. 20 . The method of claim 17 , wherein the composition comprises 0.1 μg/mg to 1 mg/mg of the isolated peptide. 21 . The method according to claim 17 , wherein the peptide is administered in a single dose at a concentration of 0.1 μg/kg to 1.0 g/kg. 22 . The method according to claim 17 , wherein the peptide is administered in a single dose at a concentration of 1 μg/kg to 10 mg/kg. 23 . The method according to claim 17 , wherein the peptide is administered 1 to 3 times a day. 24 . The method of claim 17 , wherein the peptide is administered at a daily dose of 0.1 μg/kg to 1.0 g/kg. 25 . The method of claim 17 , wherein the peptide is administered 1 to 3 times daily.
Assignees
Inventors
Classifications
the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala · CPC title
for bone diseases, e.g. rachitism, Paget's disease · CPC title
with incorporation of two atoms of oxygen (1.13.11) · CPC title
Drugs for skeletal disorders · CPC title
and aromatic or cycloaliphatic · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2022331407A1 cover?
- The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises SEQ ID NO: 1, the peptide has above 80% homology of amino acid sequence with above-mentioned sequence, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the …
- Who is the assignee on this patent?
- Kim Sang Jae, Gemvax & Kael Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C12N9/1276. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Oct 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).